Chemokine Therapeutics Corp.
This article was originally published in Start Up
Executive Summary
Cytokines, immune-system actors first discovered in the 1980s, have been developed into some very important drugs--like Amgen's blockbuster erythropoietin (Neupogen). Now Chemokine Therapeutics Corp. is seeking to develop peptides that mimic or antagonize a member of a subclass of these proteins known as chemokines. The lead candidate may help protect patients' stem cells from the destructive power of chemotherapy.
You may also be interested in...
Super-Specialist CROs: Commercializing Pharma R&D Expertise
Outsourcing is not just for mundane pharma services anymore. Increasingly, drugmakers are contracting for specialized R&D assistance they expect to provide strategic as well as tactical advantages.
Spero Therapeutics: Remodeling Antibiotics
Like other companies investigating entirely new ways of treating bacterial infections, biotech start-up Spero is increasingly aware that novel antibiotics may need to travel new clinical and regulatory pathways to market.
RxMP Therapeutics LLC
RxMP Therapeutics LLC is working to resolve excessive diffuse bleeding that is often associated with trauma, and also with certain orthopedic and cardiovascular surgeries. The start-up believes it can successfully treat excessive diffuse bleeding with particles produced from the membranes of red blood cells that have been freeze-dried and then, literally, blown to bits.